BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.36 – $1.42
Volume7,290
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.96M
Price / earnings
—
Price / book
0.65×
Price / sales
5.48×
EV / sales
-3.22×
EV / EBITDA
0.08×
Profitability
Earnings per share
-$8.01
Return on assets
-238.27%
Return on equity
-365.43%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.35×
Quick ratio
2.35×
Cash ratio
1.93×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BRTX, quarterly periods
Line item
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Q2 FY2024 Jun 30, 2024
Revenue
$23.17K
$19.6K
$11.8K
$303.3K
$25K
$43.3K
$233.6K
$89.1K
Cost of revenue
$7.39K
$1.64K
$10.57K
$8.73K
$2.91K
$3.34K
$18.24K
$6.49K
Gross profit
$15.79K
$17.96K
$1.23K
$294.57K
$22.09K
$39.96K
$215.36K
$82.61K
Selling, general and administrative
$1.48M
$1.22M
$1.12M
$1.37M
$2.18M
$1.03M
$1.05M
$1.1M
Research and development
$1.93M
$2.63M
$2.59M
$2.23M
$2.65M
$1.7M
$1.45M
$1.45M
Total operating expenses
$3.4M
$3.84M
$3.71M
$3.6M
$4.83M
$2.73M
$2.5M
$2.55M
Operating income
-$3.39M
-$3.83M
-$3.71M
-$3.31M
-$4.81M
-$2.69M
-$2.29M
-$2.47M
Interest expense
$0
$34.59K
$57.74K
$73.92K
$0
$118.99K
$158.55K
$175.95K
Income before taxes
-$2.15M
-$3.21M
-$3.04M
-$2.66M
-$5.34M
-$1.64M
-$1.09M
-$4.03M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.15M
-$3.21M
-$3.04M
-$2.66M
-$5.34M
-$1.64M
-$1.09M
-$4.03M
Net income attributable to common shareholders
-$2.15M
-$3.21M
-$3.04M
-$2.66M
-$5.34M
-$1.64M
-$1.09M
-$4.03M
EBITDA
-$3.33M
-$3.77M
-$3.66M
-$3.25M
-$4.76M
-$2.64M
-$2.24M
-$2.42M
Basic earnings per share
-$2.40
-$6.57
-$6.60
-$6.00
-$12.80
-$4.02
-$2.60
-$10.00
Diluted earnings per share
-$2.40
-$6.57
-$6.60
-$6.00
-$12.80
-$4.02
-$2.60
-$10.00
Recent news
Company coverage with links to the original publishers.
BioRestorative Therapies announced completion of dosing in its Phase 2 clinical trial for BRTX-100, treating 99 patients with chronic lumbar disc disease. The randomized, double-blind, sham-controlled study has advanced to blinded follow-up with topline safety and efficacy data expected in Q2 2027. The company received FDA alignment on Phase 3 development pathway following a Type B meeting, with no clinical safety concerns raised.
BioRestorative Therapies presented preclinical data at ISCT 2026 demonstrating that extracellular vesicles derived from different mesenchymal stem cell sources exhibit distinct protein signatures and functional properties. The findings support development of targeted exosome-based formulations for regenerative and aesthetic applications, with implications for the company's BioCosmeceutical platform spanning skin rejuvenation, wound repair, and hair health applications.
BioRestorative Therapies will participate in the Be+Well Beauty and Wellness Show (March 8-10, 2026) to expand commercialization of its BioCosmeceutical platform. The company's commercial leadership team will engage with industry partners and distributors to discuss product adoption and deployment of regenerative skincare technologies. BioRestorative positions itself as a differentiated biotech player in the emerging regenerative aesthetics market, leveraging its cGMP-compliant manufacturing and scientific infrastructure.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced the closing of a public offering of 14,285,715 shares and accompanying warrants at $0.35 per share, raising approximately $5.0 million in gross proceeds. The company plans to use the funds for clinical trials of BRTX-100 (a stem cell therapy for disc/spine disease), pre-clinical research on its ThermoStem Program (for metabolic disorders), development of its commercial biocosmeceuticals platform, and general corporate purposes.
BioRestorative Therapies (NASDAQ:BRTX) announced the pricing of a public offering of approximately 14.3 million shares and warrants at $0.35 per share, expected to raise $5.0 million in gross proceeds. The company plans to use the funds for clinical trials of BRTX-100, pre-clinical research for its ThermoStem Program, development of its biocosmeceuticals platform, and general corporate purposes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.